[
  {
    "ts": null,
    "headline": "Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results",
    "summary": "FOSTER CITY, Calif., November 27, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the company’s pivotal Phase 3 PURPOSE 2 trial evaluating twice-yearly lenacapavir for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people.",
    "url": "https://finnhub.io/api/news?id=28157046f8843d28c2eafca29fa08799b1fc9061537880fd40a257197c67e884",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732744800,
      "headline": "Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results",
      "id": 131683109,
      "image": "https://s.yimg.com/ny/api/res/1.2/kR7kUc5EzjWsoS.R8E1JQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/bd603189914349a357dbee45010d798c",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., November 27, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the company’s pivotal Phase 3 PURPOSE 2 trial evaluating twice-yearly lenacapavir for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people.",
      "url": "https://finnhub.io/api/news?id=28157046f8843d28c2eafca29fa08799b1fc9061537880fd40a257197c67e884"
    }
  }
]